Cycle Pharmaceuticals has entered into an exclusive US commercialisation agreement with Handa Therapeutics for Phyrago, an FDA-approved drug used to treat Philadelphia chromosome-positive chronic myeloid leukaemia (Ph+ CML) and acute lymphoblastic leukaemia (Ph+ ALL). Marking Cycle Pharma’s first foray into oncology, Phyrago becomes the company’s ninth commercial product and expands its mission to support patients with chronic and complex conditions.

Phyrago is a novel formulation of dasatinib (the active ingredient in Sprycel) and is uniquely designed to be safely administered with proton pump inhibitors (PPIs) and H2 receptor antagonists (H2RAs)—a critical advantage for patients who require both treatments. Unlike Sprycel, which sees dasatinib exposure reduced by over 40–60% when taken with these acid-reducing agents, Phyrago maintains consistent bioavailability without significant clinical compromise.

The product is scheduled for launch in September 2025, with comprehensive patient support provided by Cycle Vita, Cycle Pharma’s patient services platform. This includes personalised educational, financial, and access support for eligible adult patients.

“We are thrilled to expand into oncology with our second collaboration with Handa,” said Chikai Lai, SVP & Chief Commercial Officer at Cycle Pharmaceuticals. “Phyrago reflects our continued commitment to delivering individualised care—this time for patients living with leukaemia.”

Bill Liu, President & CEO of Handa Therapeutics, commented, “We are proud to bring to market the only dasatinib product that can be co-administered with PPIs and H2RAs, helping patients maintain effective treatment without compromise.”

Phyrago is indicated for newly diagnosed adults with Ph+ CML (chronic phase), those with resistance or intolerance to prior therapies including imatinib, and for Ph+ ALL patients with similar therapeutic history.

Founded in 2012, Cycle Pharmaceuticals specialises in treatments for rare genetic conditions across metabolic, immunological, urological, neurological, and now oncology domains. Handa Therapeutics focuses on developing specialty pharmaceuticals that address unmet clinical needs with high-quality formulations.